How Has the Congestive Heart Failure Treatment Devices Market Evolved Historically and What is its Current Size?
The congestive heart failure treatment devices market has seen considerable growth due to a variety of factors.
• The congestive heart failure treatment devices market has shown strong growth in recent years. It is expected to rise from $19.61 billion in 2024 to $21.21 billion in 2025, at a compound annual growth rate (CAGR) of 8.1%.
The growth is attributed to the trend towards less invasive surgical methods, the demand for minimally invasive structural heart devices, ongoing training programs for healthcare professionals, rising healthcare spending, and patients' preference for non-invasive treatments.
What is the Forecasted Market Size and CAGR for the Congestive Heart Failure Treatment Devices Market?
The congestive heart failure treatment devices market is expected to maintain its strong growth trajectory in upcoming years.
• The congestive heart failure treatment devices market will grow to $28.64 billion by 2029, at a CAGR of 7.8%.
This growth is attributed to the aging population, heightened heart health awareness, screening programs, favorable reimbursement policies, and faster regulatory approvals for new devices. Major trends include the adoption of transcatheter valve replacement, development of new devices with advanced materials, personalized treatments, hybrid procedures, and remote monitoring solutions.
What Key Factors and Trends Are Driving The Growth Congestive Heart Failure Treatment Devices Market?
The increasing prevalence of cardiovascular disorders is expected to drive growth in the congestive heart failure treatment devices market. The rise in cardiovascular disorders, such as heart attacks and coronary artery disease, is linked to factors like obesity, aging populations, and sedentary lifestyles. Congestive heart failure treatment devices are essential for managing these disorders by improving heart function and regulating rhythms. In January 2024, a report from Charity Today revealed that over 39,000 people in England died prematurely from cardiovascular conditions in 2022, highlighting the demand for heart failure treatment devices.
What Are The Market Segments In The Congestive Heart Failure Treatment Devices Market?
The congestive heart failure treatment devices market covered in this report is segmented –
1) By Product: Cardiac Pacemaker, Implantable Cardioverter Defibrillators (ICDs), Cardiac Resynchronization Therapy Devices (CRT), Counter Pulsation Devices, Ventricular Assist Devices (VADs)
2) By Application: Left Ventricular Assist Device (LVAD), Right Ventricular Assist Device (RVAD), Biventricular Assist Device (BIVAD)
3) By End-User: Hospitals And Clinic, Specialized Cardiovascular Disease Treatment Centers, Ambulatory Surgery Centers
Subsegments:
1) By Cardiac Pacemaker: Single Chamber Pacemaker, Dual Chamber Pacemaker, Biventricular Pacemaker
2) By Implantable Cardioverter Defibrillators (ICDs): Traditional ICDs, Subcutaneous ICDs, CRT-D (Cardiac Resynchronization Therapy Defibrillator)
3) By Cardiac Resynchronization Therapy Devices (CRT): CRT-P (Cardiac Resynchronization Therapy Pacemaker), CRT-D (Cardiac Resynchronization Therapy Defibrillator)
4) By Counter Pulsation Devices: Intra-Aortic Balloon Pumps (IABP), External Counterpulsation Devices (ECP)
5) By Ventricular Assist Devices (VADs): Left Ventricular Assist Devices (LVAD), Right Ventricular Assist Devices (RVAD), Biventricular Assist Devices (BiVAD)
Pre-Book The Congestive Heart Failure Treatment Devices Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Congestive Heart Failure Treatment Devices Market?
Leading companies in the congestive heart failure treatment devices market are creating innovative products like dual-chamber leadless pacemakers to improve heart rhythm synchronization, reduce risks linked to traditional pacemaker leads, increase patient comfort, and better manage heart failure symptoms, which can also reduce hospital readmissions for arrhythmia patients. For example, in February 2022, Abbott Laboratories announced the successful implantation of the first dual-chamber leadless pacemaker in a clinical trial, which offers a less invasive approach to heart rhythm management and improves overall quality of life. The device monitors heart health using advanced technology to ensure continuous oversight.
Who Are the Key Players In The Congestive Heart Failure Treatment Devices Market?
Major companies operating in the congestive heart failure treatment devices market are:
• Abbott Laboratories
• Medtronic plc
• Baxter International Inc.
• Boston Scientific Corporation
• Terumo Corporation
• Edwards Lifesciences Corporation
• Charles River Laboratories International Inc.
• W. L. Gore & Associates Inc.
• Bracco Group
• LivaNova PLC
• Meril Life Sciences Pvt. Ltd.
• Biotronik SE & Co. KG
• CryoLife Inc.
• HeartWare International Inc.
• Direct Flow Medical Inc.
• Berlin Heart GmbH
• CVRx Inc.
• Micro Interventional Devices Inc.
• Jarvik Heart Inc.
• CardioKinetix Inc.
• Xeltis AG
• Ancora Heart Inc.
• ReliantHeart Inc.
What Are The Regional Insights Into The Congestive Heart Failure Treatment Devices Market?
North America was the largest region in the congestive heart failure treatment devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure treatment devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
